Journal
FRONTIERS IN NUTRITION
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnut.2022.810472
Keywords
cancer; immune checkpoint inhibitors; hyperprogressive disease; outcome; immunotherapy
Categories
Funding
- Nature Science Foundation of Gansu Province [21JR7RA618]
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) have shown improved long-term survival in cancer patients, but a subset of nonresponsive patients may experience hyperprogressive disease (HPD), which is associated with poor prognosis. More precise parameters are needed to predict and evaluate the response pattern to ICIs.
Immune checkpoint inhibitors (ICIs) have shown durable remissions and improved long-term survival across a variety of cancer types. However, there is growing evidence that a significant subset of nonresponsive patients may exhibit hyperprogressive disease (HPD) during the initiation of immune checkpoint inhibitors (ICIs). Moreover, patients with HPD triggered by ICIs are always correlated with a deteriorating quality of life and poor prognosis. The ability to predict such rapid disease progression phenotypes is of great importance. More precision parameters to evaluate the response pattern to ICIs are urgently needed. To date, the mechanisms of HPD are still unclear. Aberrant alterations of driven genes, tumor microenvironment, or T cell immunophenotype may involve in HPD. In this article, we aim to provide an updated overview of available studies on HPD and summarize the potential predictors associated with HPD and the underlying mechanisms of HPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available